Scientists discover novel chemical that controls cell behavior

UNM Cancer Center scientists discover first-in-class chemical compound that might control metastases

2013-03-14

(Press-News.org) March 12, 2013 — Albuquerque, NM (UNM Cancer Center) — It's the spread of the original cancer tumor that kills most people. That's why cancer researchers vigorously search for drugs that can prevent metastases, the spread of cancer. The research team co-led by Angela Wandinger-Ness, PhD, and Larry Sklar, PhD, at the University of New Mexico Cancer Center has found a chemical compound that appears to control cell migration and adhesion, two important characteristics of metastatic cancer cells. The team recently published a paper describing how the first-in-class compound acts on various cells.

Dr. Wandinger-Ness, a UNM Professor of Pathology and Director of the Fluorescence Microscopy and Cell Imaging Shared Resource, studies proteins called GTPases. GTPases act like chemical switches to control how cells behave: how much a cell grows, what shape it assumes, when it enters the next growth stage, and how tightly it sticks to its surroundings, among several hundred other things. Dr. Wandinger-Ness was interested in a particular GTPase called Cdc42; it controls cell migration and cell adhesion. "It's an important target in many diseases," says Dr. Wandinger-Ness. "Cancer is just one. But there were no compounds that target this GTPase." So she collaborated with Dr. Sklar and Tudor Oprea, MD, PhD, to find a compound that did. And they were successful.

Dr. Sklar is a UNM Professor of Pathology and co-Leader of the Cancer Biology and Biotechnology Research Group at the UNM Cancer Center. He created and now oversees the UNM Center for Molecular Discovery. Dr. Oprea is a UNM Professor of Medicine and co-Director of the Flow Cytometry & High Throughput Screening Shared Resource at the UNM Cancer Center. He analyzed Cdc42 using three-dimensional molecular rendering software. The team used Dr. Oprea's analysis of Cdc42 to visualize how a compound might interact with the Cdc42 GTPase to stifle its activity. Then they searched for such a compound in the UNM Molecular Discovery library.

The search process was akin to finding a needle in a haystack, but the latest high throughput flow cytometry equipment and molecular rendering software available at the UNM Cancer Center speeded their analysis significantly. The team analyzed thousands of compound candidates by first narrowing their search to the few hundred likely candidates and then testing those against several kinds of GPTases at a time. "From a purely discovery perspective, that's a high impact, novel way to look for small molecules," says Dr. Sklar. The compound they found is called CID2950007.

Structurally similar to NSAIDs — non-steroidal anti-inflammatory drugs — CID2950007 restrains the Cdc42 GTPase from changing a cell's cytoskeleton. Much like a skeleton gives a human body shape, a cell's cytoskeleton keeps the cell from collapsing on itself. The cytoskeleton enables a cell to move by growing amoeba-like legs called filopodia. Cdc42 also helps to keep cells where they need to be by enabling them to adhere more tightly to their surroundings. So, while uncontrolled growth and movement are hallmarks of metastatic cancer cells, growth and adherence are important traits for healthy cells. Tightly controlling just how Cdc42 causes a cell to behave is crucial.

In the paper published February 4, 2013, the team of scientists report that CID2950007 was the only compound they found that affected the Cdc42 GTPase without affecting any other GTPases. This selectivity is important to control the compound's effects on a cell. They also found that the compound works by changing the physical structure of Cdc42, so it doesn't destroy Cdc42 but it does control how Cdc42 interacts with other proteins in the cell. Their studies showed that CID2950007 decreased filopodia growth and cell adhesion in ovarian cancer cells and prevented cell adhesion in white blood cells. And their studies demonstrated that CID2950007 blocked Hantavirus infection in monkey kidney cells. By affecting the Cdc42 GTPase, and thus the cytoskeleton, CID2950007 has the potential to fight not only cancer but also infectious diseases.

Human use of CID2950007 as a cancer drug is a long way off. Before the Food and Drug Administration approves any drug for human use, it first requires the successful results of several toxicity and dose escalation studies on several types of animals. Then, the clinical trials process, which can take over 10 years, may begin.

"There are going to be a lot of side effects because these adhesion proteins have many other functions," says Dr. Sklar. So refining CID2950007 into a drug will take further collaboration and studies before toxicity studies and dose escalation studies can begin. To refine the compound, the UNM Cancer Center researchers will continue to collaborate with Jeffrey Aubé, PhD, Kansas University Distinguished Professor of Medicinal Chemistry, and Jennifer Golden, PhD, Assistant Director of the Specialized Chemistry Center at Kansas University. Still, control of GTPase Cdc42 offers promise as a way to control cancer metastasis. Says Dr. Wandinger-Ness, "there's a lot of enthusiasm for a compound like this — because there weren't any. This is a first-in-class."

### Paper reference "Characterization of a Cdc42 Inhibitor and its Use as a Molecular Probe" was published online in the Journal of Biological Chemistry on February 4, 2013. Authors are: Lin Hong (University of New Mexico); S. Ray Kenney (Univerisity of New Mexico); Genevieve K. Phillips (UNM Cancer Center); Denise Simpson (Univerisity of Kansas); Chad E. Schroeder (Univerisity of Kansas); Julica Nöth (Univerisity of Kansas); Elsa Romero (University of New Mexico); Scarlett Swanson (University of New Mexico); Anna Waller (University of New Mexico); J. Jacob Strouse (University of New Mexico); Mark Carter (University of New Mexico); Alexandre Chigaev (UNM Cancer Center); Oleg Ursu (UNM Cancer Center); Tudor Oprea (UNM Cancer Center); Brian Hjelle (University of New Mexico); Jennifer E. Golden (Univerisity of Kansas); Jeffrey Aubé (Univerisity of Kansas); Laurie G. Hudson (UNM Cancer Center); Tione Buranda (University of New Mexico); Larry A. Sklar, co-senior author (UNM Cancer Center); Angela Wandinger-Ness, co-senior author (UNM Cancer Center). The paper is available to the public at: http://www.jbc.org/content/early/2013/02/04/jbc.M112.435941.full.pdf+html

About the UNM Cancer Center The UNM Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated cancer center in the state. One of just 67 NCI-designated cancer centers nationwide, the UNM Cancer Center is recognized for its scientific excellence, contributions to cancer research and delivery of medical advances to patients and their families. Annual federal and private funding of over $65 million supports the UNM Cancer Center's research programs. The UNM Cancer Center treats more than 65 percent of the adults and virtually all of the children in New Mexico affected by cancer, from every county in the state. It is home to New Mexico's largest team of board-certified oncology physicians and research scientists, representing every cancer specialty and hailing from prestigious institutions such as MD Anderson, Johns Hopkins and the Mayo Clinic. Through its partnership with Memorial Medical Center in Las Cruces, the UNM Cancer Center brings world-class cancer care to the southern part of the state; its collaborative clinical programs in Santa Fe and Farmington serve northern New Mexico. The UNM Cancer Center also supports several community outreach programs to make cancer screening, diagnosis and treatment available to every New Mexican. Learn more at http://www.cancer.unm.edu.

UNM Cancer Center contact information Dorothy Hornbeck, JKPR, (505) 340-5929, dhornbeck@jameskorenchen.com Michele Sequeira, UNM Cancer Center, (505) 925-0486, msequeira@salud.unm.edu END

ELSE PRESS RELEASES FROM THIS DATE:

Sun spits out 2 CMEs

2013-03-14

The sun recently erupted with two coronal mass ejections (CMEs). One began at 8:36 p.m. EDT on March 12, 2013 and is directed toward three NASA spacecraft, Spitzer, Kepler and Epoxi. There is, however, no particle radiation associated with this event, which is what would normally concern operators of interplanetary spacecraft since the particles can trip computer electronics on board. A second CME began at 6:54 a.m. EDT on March 13, 2013 and its flank may pass by Earth at a speed that does not typically have a significant impact at Earth. Experimental NASA research models, ...

Vitamin D may lower blood pressure in African-Americans

2013-03-14

Boston – High blood pressure, a risk factor for heart attacks, heart failure and stroke, is 40 percent more common in African-Americans than in other American ethnic groups. In a new study from Brigham and Women's Hospital (BWH), along with the Dana-Farber Cancer Institute and Massachusetts General Hospital, researchers show that vitamin D supplementation may help African-Americans lower their blood pressure. The study publishes online in the March 13, 2013 edition of the American Heart Association journal Hypertension. "This study may explain and help treat an important ...

US lifespans lags other high-income countries, tied to mortality rates under age 50

2013-03-14

Higher mortality rates among Americans younger than 50 are responsible for much of why life expectancy is lower in the United States than most of the world's most developed nations. The research, by Jessica Ho, a University of Pennsylvania doctoral candidate in demography and sociology, found that excess mortality among Americans younger than 50 accounted for two-thirds of the gap in life expectancy at birth between American males and their counterparts and two-fifths between females and their counterparts in the comparison countries. The study, "Mortality Under Age ...

Foundations of carbon-based life leave little room for error

2013-03-14

Life as we know it is based upon the elements of carbon and oxygen. Now a team of physicists, including one from North Carolina State University, is looking at the conditions necessary to the formation of those two elements in the universe. They've found that when it comes to supporting life, the universe leaves very little margin for error. Both carbon and oxygen are produced when helium burns inside of giant red stars. Carbon-12, an essential element we're all made of, can only form when three alpha particles, or helium-4 nuclei, combine in a very specific way. The ...

UI study of Midwest finds increase in heavy rainfalls over 60 years

2013-03-14

Heavy rains have become more frequent in the upper Midwest over the past 60 years, according to a study from the University of Iowa. The trend appears to hold true even with the current drought plaguing the region, the study's main author says. The fact that temperatures over the country's midsection are rising, too, may be more than coincidence.The hotter the surface temperature, which has been the trend in the Midwest and the rest of the world, the more water that can be absorbed by the atmosphere. And the more water available for precipitation means a greater chance ...

Video game 'exercise' for an hour a day may enhance certain cognitive skills

2013-03-14

Playing video games for an hour each day can improve subsequent performance on cognitive tasks that use similar mental processes to those involved in the game, according to research published March 13 in the open access journal PLOS ONE by Adam Chie-Ming Oei and Michael Donald Patterson of Nanyang Technological University, Singapore. Non-gamer participants played five different games on their smartphones for an hour a day, five days of the week for one month. Each participant was assigned one game. Some played games like Bejeweled where participants matched three identical ...

Series of studies first to examine acupuncture's mechanisms of action

2013-03-14

WASHINGTON — While acupuncture is used widely to treat chronic stress, the mechanism of action leading to reported health benefits are not understood. In a series of studies at Georgetown University Medical Center (GUMC), researchers are demonstrating how acupuncture can significantly reduce the stress hormone response in an animal model of chronic stress. The latest study was published today in the April issue of Journal of Endocrinology. "Many practitioners of acupuncture have observed that this ancient practice can reduce stress in their patients, but there is a ...

Brain stent offers alternative to shunt for fixing potentially blinding vein narrowing

2013-03-14

A team of interventional neuroradiologists and neurosurgeons at Johns Hopkins reports wide success with a new procedure to treat pseudotumor cerebri, a rare but potentially blinding condition marked by excessive pressure inside the skull, caused by a dangerous narrowing of a vein located at the base of the brain. The Johns Hopkins team's latest study, to be published in the Journal of Neuro-Ophthalmology online March 14, is believed to be the first to show how directly lowering pressure inside the vein alleviates the condition and improves vision. The study report on ...

Garbled text messages may be the only symptoms of stroke

2013-03-14

DETROIT – Difficulty or inability to write a coherent text message, even in patients who have no problem speaking, may become a "vital" tool in diagnosing a type of crippling stroke, according to new research at Henry Ford Hospital. The case study focused on a 40-year-old man visiting the metro Detroit area on business who showed signs of "dystextia," a recently coined term for incoherent text messaging that can sometimes be confused with autocorrect garble. But in his case, the man saw nothing wrong with the garble. The patient had no problem with a routine bedside ...

Rapid hearing loss may be a symptom of rare Creutzfeldt-Jakob Disease

2013-03-14

DETROIT – Rapid hearing loss in both ears may be a symptom of the rare but always-fatal Creutzfeldt-Jakob Disease and should be considered a reason for clinicians to test for the disorder. That was the conclusion of Henry Ford Hospital researchers after encountering a 67-year-old patient who had been progressively losing hearing in both ears for two months and was eventually diagnosed with the disease. Creutzfeldt-Jakob Disease, or CJD, is often confused with so-called "mad cow disease," and though they are in the same family of disorders, are not the same. However, ...

ACS Central Science | Researchers from Insilico Medicine and Lilly publish foundational vision for fully autonomous “Prompt-to-Drug” pharmaceutical R&D

Increasing the number of coronary interventions in patients with acute myocardial infarction does not appear to reduce death rates

Striking genomic architecture discovered in embryonic reproductive cells before they start developing into sperm and eggs

AABNet and partners launch landmark guide on the conservation of African livestock genetic resources and sustainable breeding strategies

Produce hydrogen and oxygen simultaneously from a single atom! Achieve carbon neutrality with an 'All-in-one' single-atom water electrolysis catalyst

Sleep loss linked to higher atrial fibrillation risk in working-age adults

Visible light-driven deracemization of α-aryl ketones synergistically catalyzed by thiophenols and chiral phosphoric acid

Babies with an increased likelihood of autism may struggle to settle into deep, restorative sleep, according to a new study from the University of East Anglia.

National Reactor Innovation Center opens Molten Salt Thermophysical Examination Capability at INL

International Progressive MS Alliance awards €6.9 million to three studies researching therapies to address common symptoms of progressive MS

[Press-News.org] Scientists discover novel chemical that controls cell behavior
UNM Cancer Center scientists discover first-in-class chemical compound that might control metastases

Scientists discover novel chemical that controls cell behavior

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: